Welcome to DailyUpdates Infectious diseases - the R&D community's bulletin of breaking research, clinical trials and drug development news. This page will update each day. You have access for 1 more day(s). To receive DailyUpdates by e-mail register here


PubMed DailyUpdates: Breaking Scientific Publications for the Drug Discovery Community

DailyUpdates by e-mail - the publication tracker for the drug discovery community

Infectious diseases



If this icon appears after any of our listed articles, the author is able to provide reprints. Articles denoted by an Licensing Op. icon describe data relevant to licensing opportunities. The report icon, , links through to full analyses relating to pharmaceutical/market developments relating to this work

Facebook

Today's journal articles

No journal articles today

Do you need further information on any of the agents being evaluated in the trial(s) below?  Let us know...

New Clinical Trials

Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults

Previous Journal Entries

IL-23, Independent of IL-17 and IL-22, Drives Neutrophil Recruitment and Innate Inflammation During Clostridium difficile Colitis in Mice.

Synthesis, Crystal Structure and Biological Activity Screening of Novel N-(α-Bromoacyl)-α-amino Esters Containing Valyl Moiety.

Intranasal Immunization with DOTAP Cationic Liposomes Combined with DC-Cholesterol Induces Potent Antigen-Specific Mucosal and Systemic Immune Responses in Mice.

Di-N-Methylation of Anti-Gram-Positive Aminoglycoside-Derived Membrane Disruptors Improves Antimicrobial Potency and Broadens Spectrum to Gram-Negative Bacteria.

Generation and Characterisation of ALX-0171, a potent novel therapeutic Nanobody® for the treatment of Respiratory Syncytial Virus infection.

Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis.

Discovery of Indoline - 2 - carboxamide Derivatives as a New Class of Brain - Penetrant Inhibitors of Trypanosoma brucei.

Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells.

In silico discovery and in vitro validation of catechol-containing sulfonohydrazide compounds as potent inhibitors of the diguanylate cyclase PleD.

Synthesis and structure - activity studies of the V - ATPase inhibitor saliphenylhalamide (SaliPhe) and simplified analogs.

Design of HIV - 1 Protease Inhibitors with Amino - bis - tetrahydrofuran Derivatives as P2 - Ligands to Enhance Backbone - Binding Interactions: Synthesis, Biological Evaluation, and Protein - Ligand X - ray Studies.

TNFAIP2 Inhibits Early TNFα-Induced NF-x03BA;B Signaling and Decreases Survival in Septic Shock Patients.

The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.

Selective inhibition of HIV-1 replication by the CDK9 inhibitor FIT-039.

Development of Small - molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

Fragment Based Strategies for Discovery of Novel HIV - 1 Reverse Transcriptase and Integrase Inhibitors.

GS-5806 Inhibits Pre- to Post-fusion Conformational Changes of the RSV Fusion Protein.

Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly.

Inhibition of Shikimate Kinase and Type II Dehydroquinase for Antibiotic Discovery: Structure - Based Design and Simulation Studies.

Structure Activity Relationship Studies of Orally Active Antimalarial 2,4 - Diamino - thienopyrimidines.

Today's News Items

CONTRAVIR REPORTS POSITIVE DATA FROM PHASE 1B STUDY OF CMX157; HEAD-TO-HEAD PHASE 2A STUDY VS. VIREAD ONGOING IN HEPATITIS B PATIENTS

Training Courses & Meetings

No events listed

Previous News Items

Novan Announces First Patient Dosed in Phase 2 Anti-Fungal Program

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trials Safety Review Committee

AstraZenecas antibiotic Zavicefta met primary endpoints in Phase III trial for treatment of hospital-acquired pneumonia

Merck Provides Regulatory Update on Biologics Licensing Application for Investigational Agent Bezlotoxumab

Data for Merck's Investigational Once-Daily Formulation of ISENTRESS (raltegravir) Show That at Week 48, a Regimen Containing the Once-Daily Dosing Formulation

European CHMP Adopts Positive Opinion on Gileads Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV

Merck Receives Breakthrough Therapy Designation from FDA and PRIME Status from EMA for Investigational Ebola Zaire Vaccine (V920)

AbbVie Receives U.S. FDA Approval of Once-Daily VIEKIRA XR (dasabuvir, ombitasvir, paritaprevir and ritonavir) for the Treatment of Genotype 1 Chronic Hepatitis C